BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32899355)

  • 1. Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis.
    Oliinyk D; Augustin T; Koehler VF; Rauch J; Belka C; Spitzweg C; Käsmann L
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients.
    Augustin T; Oliinyk D; Köhler VF; Rauch J; Belka C; Spitzweg C; Käsmann L
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution.
    Takahashi N; Matsushita H; Umezawa R; Yamamoto T; Ishikawa Y; Katagiri Y; Tasaka S; Takeda K; Fukui K; Kadoya N; Ito K; Jingu K
    Eur Thyroid J; 2019 Jan; 8(1):24-30. PubMed ID: 30800638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.
    Pezzi TA; Mohamed ASR; Sheu T; Blanchard P; Sandulache VC; Lai SY; Cabanillas ME; Williams MD; Pezzi CM; Lu C; Garden AS; Morrison WH; Rosenthal DI; Fuller CD; Gunn GB
    Cancer; 2017 May; 123(9):1653-1661. PubMed ID: 28026871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.
    Oliinyk D; Augustin T; Rauch J; Koehler VF; Belka C; Spitzweg C; Käsmann L
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3527-3547. PubMed ID: 35960373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer.
    Oweida A; Phan A; Vancourt B; Robin T; Hararah MK; Bhatia S; Milner D; Lennon S; Pike L; Raben D; Haugen B; Pozdeyev N; Schweppe R; Karam SD
    Thyroid; 2018 Jun; 28(6):739-747. PubMed ID: 29774792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
    Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes of radiotherapy for anaplastic thyroid cancer.
    Park JW; Choi SH; Yoon HI; Lee J; Kim TH; Kim JW; Lee IJ
    Radiat Oncol J; 2018 Jun; 36(2):103-113. PubMed ID: 29983030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal treatment based on thyroidectomy improves survival in patients with metastatic anaplastic thyroid carcinoma: a SEER analysis from 1998 to 2015.
    Song T; Chen L; Zhang H; Lu Y; Yu K; Zhan W; Fang M
    Gland Surg; 2020 Oct; 9(5):1205-1213. PubMed ID: 33224795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
    Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External beam radiation dose escalation for high grade glioma.
    Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
    Cochrane Database Syst Rev; 2016 Aug; (8):CD011475. PubMed ID: 27541334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of radiotherapy in anaplastic thyroid cancer.
    Dumke AK; Pelz T; Vordermark D
    Radiat Oncol; 2014 Mar; 9(1):90. PubMed ID: 24685141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
    Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
    Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
    Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors.
    Harris JP; Chang-Halpenny CN; Maxim PG; Quon A; Graves EE; Diehn M; Loo BW
    Clin Lung Cancer; 2015 Nov; 16(6):475-85. PubMed ID: 25770888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer.
    Levy A; Leboulleux S; Lepoutre-Lussey C; Baudin E; Ghuzlan AA; Hartl D; Deutsch E; Deandreis D; Lumbroso J; Tao Y; Schlumberger M; Blanchard P
    Oral Oncol; 2015 Apr; 51(4):370-5. PubMed ID: 25595614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
    Prasongsook N; Kumar A; Chintakuntlawar AV; Foote RL; Kasperbauer J; Molina J; Garces Y; Ma D; Wittich MAN; Rubin J; Richardson R; Morris J; Hay I; Fatourechi V; McIver B; Ryder M; Thompson G; Grant C; Richards M; Sebo TJ; Rivera M; Suman V; Jenkins SM; Smallridge RC; Bible KC
    J Clin Endocrinol Metab; 2017 Dec; 102(12):4506-4514. PubMed ID: 29029287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management trends for anaplastic meningioma with adjuvant radiotherapy and predictors of long-term survival.
    Alhourani A; Aljuboori Z; Yusuf M; Woo SY; Hattab EM; Andaluz N; Williams BJ
    Neurosurg Focus; 2019 Jun; 46(6):E4. PubMed ID: 31153143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.